Фармакокинетика, безопасность и эффективность схемы на основе полной дозы софосбувира, принимаемой ежедневно, у больных хроническим гепатитом C, находящихся на гемодиализе
Aude Desnoyer1,a, Dan Pospai2, Minh Patrick Le1, Anne Gervais3, Alexandra Heurgue-Berlot4, Achour Laradi5, Stanislas Harent3, Adriana Pinto3, Dominique Salmon6, Sophie Hillaire7, Helene Fontaine8, David Zucman9, Anne-Marie Simonpoli10, Patrice Muret11, Lucile Larrouy12,13, Brigitte Bernard Chabert4, Diane Descamps12,13, Yazdan Yazdanpanah3, Gilles Peytavin1,13
1 Pharmaco-Toxicology Department, Bichat-Claude Bernard Hospital, APHP, Paris, France; 2 Gastroenterology Department, Bichat-Claude Bernard Hospital, APHP, Paris, France; 3 Infectious Diseases & Tropical Department, Bichat-Claude Bernard Hospital, APHP, Paris, France; 4 Gastroenterology Department, Robert Debre Hospital, Reims, France; 5 Nephrology Department, ECHO-CMCM, Le Mans, France; 6 Internal Medicine Department, Cochin Hospital, APHP, Paris Descartes University, Sorbonne Paris Cite, Paris, France; 7 Gastroenterology Department, Foch Hospital, Suresnes, France; 8 Gastroenterology Department, Cochin Hospital, APHP, Paris Descartes University, Sorbonne Paris Cite, Inserm U1016, Paris, France; 9 Infectious Diseases Department, Foch Hospital, Suresnes, France; 10 Internal Medicine Department, Louis-Mourier Hospital, APHP, Colombes, France; 11 Clinical Pharmaco-Toxicology Department, University Hospital of Besancon, INSERM U1098, Besancon, France; 12 Virology Department, Bichat-Claude Bernard Hospital, APHP, Paris, France; 13 Universite Paris Diderot, Sorbonne Paris Cite, IAME, INSERM UMR 1137, Paris, France
* Автор, ответственный за переписку.
Шкала PAGE-B для прогнозирования гепатоцеллюлярного рака у белых пациентов с хроническим гепатитом B, принимающих противовирусные средства в течение 5 лет
George Papatheodoridis1,2,*, George Dalekos3, Vana Sypsa4, Cihan Yurdaydin5, Maria Buti6, John Goulis7, Jose Luis Calleja8, Heng Chi9, Spilios Manolakopoulos2, Giampaolo Mangia10, Nikolaos Gatselis3, Onur Keskin5, Savvoula Savvidou7, Juan de la Revilla8, Bettina E.
Лактат-ацидоз у пациентов с циррозом на фоне гепатита C, получающих комбинированное лечение рибавирином и софосбувиром
Martin-Walter Welker1,*, Stefan Luhne1, Christian M. Lange1, Johannes Vermehren1, Harald Farnik1, Eva Herrmann2, Tania Welzel1, Stefan Zeuzem1, Christoph Sarrazin1
1 Medizinische Klinik 1, Universitatsklinikum Frankfurt, Theodor-Stern-Kai 7, 60590 Frankfurt, Germany; 2 Institut fur Biostatistik und Mathematische Modellierung, Goethe Universitat Frankfurt, Theodor-Stern-Kai 7, 60590 Frankfurt, Germany
*Автор, ответственный за переписку.
Даклатасвир и симепревир в сочетании с рибавирином или без него в лечении хронического гепатита C, вызванного вирусом генотипа 1
Stefan Zeuzem1,*, Christophe Hezode2, Jean-Pierre Bronowicki3, Veronique Loustaud-Ratti4, Francisco Gea5, Maria Buti6, Antonio Olveira5, Tivadar Banyai7, M. Tarek Al-Assi8, Joerg Petersen9, Dominique Thabut10, Adrian Gadano11, Ronald Pruitt12, Mihaly Makara13, Marc Bourliere14, Stanislas Pol15, Maria Beumont-Mauviel16, Sivi Ouwerkerk-Mahadevan17, Gaston Picchio18, Marc Bifano19, Fiona McPhee20, Navdeep Boparai19, Kin Cheung20, Eric A.
Стопроцентный устойчивый вирусологический ответ у пациентов с циррозом, инфицированных HCV генотипа 1b, получавших омбитасвир/паритапревир/ритонавир и дасабувир в течение 12 недель#
Jordan J. Feld1,*, Christophe Moreno2, Roger Trinh3, Edward Tam4, Stefan Bourgeois5, Yves Horsmans6, Magdy Elkhashab7, David E. Bernstein8, Ziad Younes9, Robert W. Reindollar10, Lois Larsen3, Bo Fu3, Kevin Howieson3, Akshanth R.
Эффективность и безопасность омбитасвира/паритапревира/ритонавира и дасабувира по сравнению со схемами, содержащими интерферон, у пациентов, инфицированных HCV генотипа 1: исследования MALACHITE-I/II
Gregory J. Dore1,*,#, Brian Conway2,#, Yan Luo3, Ewa Janczewska4, Brygida Knysz5, Yan Liu3, Adrian Streinu-Cercel6, Florin Alexandru Caruntu7, Manuela Curescu8, Richard Skoien9, Wayne Ghesquiere10, Wlodzimierz Mazur11, Alejandro Soza12, Francisco Fuster13, Susan Greenbloom14, Adriana Motoc15, Victoria Arama6, David Shaw16, Istvan Tornai17, Joseph Sasadeusz18, Olav Dalgard19, Danielle Sullivan3, Xuan Liu3, Mudra Kapoor3, Andrew Campbell3, Thomas Podsadecki3
1 Kirby Institute, UNSW Australia, and St.
Прием статинов и риск цирроза печени у больных гепатитом C
Yao-Hsu Yang1,2,3,4, Wen-Cheng Chen2,5, Yu-Tse Tsan3,6,7, Mei-Jyh Chen3,8, Wei-Tai Shih1,3, Ying-Huang Tsai9,10,*, Pau-Chung Chen3,11,*
1 Department of Traditional Chinese Medicine, Chang Gung Memorial Hospital, Chia-Yi, Taiwan; 2 Center of Excellence for Chang Gung Research Datalink, Chang Gung Memorial Hospital, Chiayi, Taiwan; 3 Institute of Occupational Medicine and Industrial Hygiene, National Taiwan University College of Public Health, Taipei, Taiwan; 4 School of Traditional Chinese Medicine, College of Medicine, Chang Gung University, Taoyuan, Taiwan; 5 Department of Radiation Oncology, Chang Gung Memorial Hospital, Chiayi, Taiwan; 6 Institute of Occupational Medicine, Department of Emergency Medicine, Taichung Veterans General Hospital, Taichung, Taiwan; 7 School of Medicine, Chung Shan Medical University, Taichung, Taiwan; 8 Departments of Internal Medicine, Integrated Diagnostics and Therapeutics, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan; 9 Division of Pulmonary and Critical Care Medicine and Department of Respiratory Care, Chang Gung Memorial Hospital, Chiayi, Taiwan; 10 Department of Respiratory Therapy, Chang Gung University, Taoyuan, Taiwan; 11 Department of Environmental and Occupational Medicine, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan
* Авторы, ответственные за переписку.
Влияние исходного генетического разнообразия вируса гепатита В на элиминацию HBsAg при лечении тенофовира дизопроксила фумаратом
Prista Charuworn1,*, Paul N. Hengen1, Raul Aguilar Schall1, Phillip Dinh1, Dongliang Ge1, Amoreena Corsa1, Hendrik W. Reesink2, Fabien Zoulim3, Kathryn M. Kitrinos1
1 Gilead Sciences, Inc, Foster City, CA, USA; 2 Department of Gastroenterology and Hepatology, Academic Medical Center, Amsterdam, The Netherlands; 3 INSERM U1052, Hospices Civils de Lyon, Lyon University, Lyon, France
* Автор, ответственный за переписку.
Характеристика новых мутаций резистентности к энтекавиру
Sanae Hayashi1, Shuko Murakami1, Katsumi Omagari1, Takeshi Matsui1,2, Etsuko Iio1, Masanori Isogawa1, Tsunamasa Watanabe1, Yoshiyasu Karino3, Yasuhito Tanaka1,*
1 Department of Virology & Liver Unit, Nagoya City University Graduate School of Medical Science, Nagoya, Japan; 2 Center for Gastroenterology, Teine Keijinkai Hospital, Sapporo, Japan; 3 Department of Gastroenterology, Sapporo Kosei General Hospital, Hokkaido, Japan
* Автор, ответственный за переписку.